Drug Trial Radar · NCT07647237
A Clinical Trial of Multiple Doses of GR2301 Injection Combined With Phototherapy in Trial Participants With Vitiligo
Last checked: Nov 19, 2026Latest source record: Jun 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
116
Planned (sponsor's estimate)
Start
Jun 2026
Primary completion
Jun 2028
Study completion Dec 2028
Sponsor
- Lead sponsor
- Genrix (Shanghai) Biopharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jun 15, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomized, double-blind, placebo-controlled Phase Ib/II clinical trial of multiple subcutaneous injections of GR2301 in combination with phototherapy to evaluate the tolerability, safety, pharmacokinetics, and preliminary efficacy in trial participants with vitiligo. The trial will be conducted in two stages: a dose-escalation stage (Phase Ib) and an expansion cohort stage (Phase II).
Conditions
- Vitiligo
Interventions
GR2301 injectionBiological
IL15 monoclonal antibody
PlaceboBiological
Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adverse events (AEs)( Phase Ib)Time frame: up to 52weeks
- Proportion of subjects achieving F-VASI 75(Phase II)Time frame: Week 24
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.